Kim Evaluates Atezolizumab and Durvalumab for ES-SCLC
September 9th 2020Edward Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute in Charlotte, NC, discussed the use of atezolizumab and durvalumab as treatment of a 73-year-old female patient with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.
Spira Analyzes the Use of Durvalumab in Unresectable Stage III NSCLC
September 7th 2020Alex Spira, MD, PhD, director, Virginia Cancer Specialists, Phase I Trial Program, Fairfax, VA, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.
Kris Details Use of Immunotherapies After Lung Cancer Progression
September 4th 2020During a virtual Case Based Peer Perspectives event, Mark G. Kris, MD, attending physician, Thoracic Oncology Service, William and Joy Ruane chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discussed molecular testing for a 59-year-old patient with poorly differentiated adenocarcinoma of the lung, as wells as the treatment options for the patient.
Efstathiou Compares the Efficacy and Safety of AR Inhibitors in Nonmetastatic CRPC
August 31st 2020During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, a discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer.
McCloskey Explores Merits of Targeted Treatments and HMAs in MDS
August 23rd 2020The options for targeted therapy and treatment with hypomethylating agents was discussed during a virtual Case Based Peer Perspectives event, which highlighted the case of a 75-year-old male patient with myelodysplastic syndromes. The discussion was led by James K. McCloskey II, MD.
Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages
May 23rd 2020In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.
FDA Approves Subcutaneous Daratumumab With Hyaluronidase in Multiple Myeloma Indications
May 1st 2020The FDA has approved the use of daratumumab in combination with hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma. The newly approved product allowed for subcutaneous dosing of daratumumab.
Aggarwal Reviews the Latest Data Related to Systemic Therapy in Stage III NSCLC
April 19th 2020In a Targeted Oncology case-based peer perspectives live discussion, Charu Aggarwal, MD, MPH, discussed systemic treatment options for stage III non–small cell lung cancer, based on a real case of a 63-year-old male patient.
Alpelisib Receives FDA Approval in Breast Cancer
May 24th 2019Based on data from the phase III SOLAR-1 trial, alpelisib (Piqray) has been approved by the FDA for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
Venetoclax/Obinutuzumab Combo Approved by FDA for Frontline CLL
May 15th 2019The combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) has been approved by the FDA for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on findings from the phase III CLL14 trial.
Erdafitinib Granted FDA Approval in Bladder Cancer
April 12th 2019Erdafitinib (Balversa) has been granted an accelerated approval by the FDA as a treatment for adult patients with locally advanced or metastatic bladder cancer with an <em>FGFR3</em> or <em>FGFR2</em> alteration that has progressed on platinum-containing chemotherapy, making it the first targeted agent to receive approval for metastatic bladder cancer.
Palbociclib Approved by FDA for Treatment of Male Patients With HR+/HER2- Breast Cancer
April 5th 2019The indication for palbociclib capsules in combination with endocrine therapy now includes the treatment of male patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer after being expanded by the FDA.
NCCN Updates Guidelines for BRAF-Mutant CRC to Include Triplet With Encorafenib And Binimetinib
March 19th 2019The clinical practice guidelines for the treatment of patients with colorectal cancer have been updated by NCCN to include the combination of encorafenib plus binimetinib in addition to EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with <em>BRAF</em> V600E–mutant metastatic CRC, after 1 or 2 prior therapies for metastatic disease.
Darolutamide Submitted for FDA Approval in Nonmetastatic CRPC
February 27th 2019Based on findings from the phase III ARAMIS trial, a new drug application for darolutamide has been submitted to the FDA seeking the investigational agent's approval as a treatment for patients with nonmetastatic castration-resistant prostate cancer, according to the codevelopers of the investigational agent, Bayer and Orion Corporation.<br />